PMZ 1620

Drug Profile

PMZ 1620

Alternative Names: PMZ1620

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Pharmazz
  • Class
  • Mechanism of Action Angiogenesis inducing agents; Neurogenesis stimulants; Neuron modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cerebrovascular disorders
  • Clinical Phase Unknown Solid tumours
  • Preclinical Neurodegenerative disorders

Most Recent Events

  • 30 Nov 2016 Phase-I clinical trials in Cerebrovascular disorders (In volunteers) in India (Injection)
  • 15 Nov 2016 Pharmazz receives US Patent No. 9 493 524 for PMZ 1620 in USA
  • 21 Sep 2016 Pharmazz has patent protection for PMZ 1620 in the US, the EU, India and China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top